Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

radboud van Luin; Marchina E Van der Ende; rijnstate Richter; Mirjam Visser; Diari Faraj; radboud Van der Ven; Luc Gelinck; Frank Kroon; Ferdinand W Wit; erasmus Van Schaik; rijnstate Kuks; radboud Burger

doi:10.1097/QAD.0b013e3283389129

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

radboud van Luin, Marchina E Van der Ende, rijnstate Richter, Mirjam Visser, Diari Faraj, radboud Van der Ven, Luc Gelinck, Frank Kroon, Ferdinand W Wit, erasmus Van Schaik, rijnstate Kuks, radboud Burger

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

Original language	English
Pages (from-to)	1223-6
Number of pages	4
Journal	AIDS (London, England)
Volume	24
Issue number	8
DOIs	https://doi.org/10.1097/QAD.0b013e3283389129
Publication status	Published - 15 May 2010
Externally published	Yes

Keywords

Adolescent
Adult
Aged
Alkynes
Atazanavir Sulfate
Atovaquone/blood
Benzoxazines/administration & dosage
Cyclopropanes
Drug Administration Schedule
Female
HIV Infections/drug therapy
HIV Protease Inhibitors
HIV-1
Humans
Lopinavir
Male
Middle Aged
Oligopeptides/administration & dosage
Proguanil/blood
Pyridines/administration & dosage
Pyrimidinones/administration & dosage
Ritonavir/administration & dosage
Young Adult

Access to Document

10.1097/QAD.0b013e3283389129

Cite this

van Luin, R., Van der Ende, M. E., Richter, R., Visser, M., Faraj, D., Van der Ven, R., Gelinck, L., Kroon, F., Wit, F. W., Van Schaik, E., Kuks, R., & Burger, R. (2010). Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS (London, England), 24(8), 1223-6. https://doi.org/10.1097/QAD.0b013e3283389129

@article{649dfb15fcdb4d1a9450a5f4a94be25f,

title = "Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir",

abstract = "HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.",

keywords = "Adolescent, Adult, Aged, Alkynes, Atazanavir Sulfate, Atovaquone/blood, Benzoxazines/administration & dosage, Cyclopropanes, Drug Administration Schedule, Female, HIV Infections/drug therapy, HIV Protease Inhibitors, HIV-1, Humans, Lopinavir, Male, Middle Aged, Oligopeptides/administration & dosage, Proguanil/blood, Pyridines/administration & dosage, Pyrimidinones/administration & dosage, Ritonavir/administration & dosage, Young Adult",

author = "{van Luin}, radboud and {Van der Ende}, {Marchina E} and rijnstate Richter and Mirjam Visser and Diari Faraj and {Van der Ven}, radboud and Luc Gelinck and Frank Kroon and Wit, {Ferdinand W} and {Van Schaik}, erasmus and rijnstate Kuks and radboud Burger",

year = "2010",

month = may,

day = "15",

doi = "10.1097/QAD.0b013e3283389129",

language = "English",

volume = "24",

pages = "1223--6",

journal = "AIDS (London, England)",

issn = "0269-9370",

publisher = "Lippincott Williams & Wilkins",

number = "8",

}

TY - JOUR

T1 - Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

AU - van Luin, radboud

AU - Van der Ende, Marchina E

AU - Richter, rijnstate

AU - Visser, Mirjam

AU - Faraj, Diari

AU - Van der Ven, radboud

AU - Gelinck, Luc

AU - Kroon, Frank

AU - Wit, Ferdinand W

AU - Van Schaik, erasmus

AU - Kuks, rijnstate

AU - Burger, radboud

PY - 2010/5/15

Y1 - 2010/5/15

N2 - HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

AB - HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0-->t for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.35-0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

KW - Adolescent

KW - Adult

KW - Aged

KW - Alkynes

KW - Atazanavir Sulfate

KW - Atovaquone/blood

KW - Benzoxazines/administration & dosage

KW - Cyclopropanes

KW - Drug Administration Schedule

KW - Female

KW - HIV Infections/drug therapy

KW - HIV Protease Inhibitors

KW - HIV-1

KW - Humans

KW - Lopinavir

KW - Male

KW - Middle Aged

KW - Oligopeptides/administration & dosage

KW - Proguanil/blood

KW - Pyridines/administration & dosage

KW - Pyrimidinones/administration & dosage

KW - Ritonavir/administration & dosage

KW - Young Adult

U2 - 10.1097/QAD.0b013e3283389129

DO - 10.1097/QAD.0b013e3283389129

M3 - Article

C2 - 20299957

SN - 0269-9370

VL - 24

SP - 1223

EP - 1226

JO - AIDS (London, England)

JF - AIDS (London, England)

IS - 8

ER -

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

Abstract

Keywords

Access to Document

Fingerprint

Cite this